Drug Approval | March 07, 2022
NATCO launches first generic version of Revlimid in the US
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
Dr. Muffazal Lakdawala performs the largest series of complete robotic gastric bypass surgery in India
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
Subscribe To Our Newsletter & Stay Updated
